Stock ONCS ONCOSEC MEDICAL INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Press Releases OncoSec Medical Inc OTC Bulletin Board

Equities

ONCS

US68234L1089

End-of-day quote OTC Bulletin Board
Other stock markets
- USD - Intraday chart for OncoSec Medical Inc
2023 Motion for Asset Sale Approved for OncoSec Medical Incorporated CI
2023 Motion for Asset Sale Filed by OncoSec Medical Incorporated CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
OncoSec Medical Incorporated : Bankruptcy - Form 8-K
PU
ONCOSEC MEDICAL INC : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)
AQ
OncoSec Announces Closing of $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
PR
OncoSec Announces $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
PR
OncoSec is encouraged after FDA meeting to discuss proposed neoadjuvant melanoma clinical program
PR
ONCOSEC MEDICAL INC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
OncoSec Receives $3.49 Million to Strengthen its Balance Sheet After Selling its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Authority NOL Program
PR
ONCOSEC MEDICAL INC : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
OncoSec Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
PR
OncoSec Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
PR
OncoSec Announces Clinical Data of the KEYNOTE-695 Trial Assessing TAVO-EP in Combination with KEYTRUDA in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment
AQ
ONCOSEC MEDICAL INC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
OncoSec Announces Clinical Data of the KEYNOTE-695 Trial Assessing TAVO™-EP in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment
PR
ONCOSEC MEDICAL INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)
AQ
Methes Energies International Ltd ($MEIL) enters into the b2 biOil and bio-lubricant sector via acquisition of EarthFriendly Products Inc
AQ
ONCOSEC MEDICAL INC : Other Events (form 8-K)
AQ
ONCOSEC MEDICAL INC : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
AQ
ONCOSEC MEDICAL INC : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)
AQ
ONCOSEC MEDICAL INC : Change in Directors or Principal Officers (form 8-K)
AQ
ONCOSEC MEDICAL INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ONCSQ Stock
  4. ONCS Stock
  5. News OncoSec Medical Inc
  6. Press Releases